A Disease State Fingerprint for Evaluation of Alzheimer's Disease

被引:70
|
作者
Mattila, Jussi [1 ]
Koikkalainen, Juha [1 ]
Virkki, Arho [1 ]
Simonsen, Anja [2 ,3 ]
van Gils, Mark [1 ]
Waldemar, Gunhild [2 ,3 ]
Soininen, Hilkka [4 ]
Lotjonen, Jyrki [1 ]
机构
[1] VTT Tech Res Ctr Finland, FIN-33101 Tampere, Finland
[2] Copenhagen Univ Hosp, Dept Neurol, Sect 2082, Copenhagen Memory Clin, Copenhagen, Denmark
[3] Copenhagen Univ Hosp, Memory Disorders Res Grp, Copenhagen, Denmark
[4] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; automatic; biomarkers; computer-assisted; decision making; information processing; projections and predictions; MILD COGNITIVE IMPAIRMENT; DEMENTIA; DIAGNOSIS; PREDICTION; CONVERSION; MARKERS; EUROPE; COHORT; MRI; MCI;
D O I
10.3233/JAD-2011-110365
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Diagnostic processes of Alzheimer's disease (AD) are evolving. Knowledge about disease-specific biomarkers is constantly increasing and larger volumes of data are being measured from patients. To gain additional benefits from the collected data, a novel statistical modeling and data visualization system is proposed for supporting clinical diagnosis of AD. The proposed system computes an evidence-based estimate of a patient's AD state by comparing his or her heterogeneous neuropsychological, clinical, and biomarker data to previously diagnosed cases. The AD state in this context denotes a patient's degree of similarity to a previously diagnosed disease population. A summary of patient data and results of the computation are displayed in a succinct Disease State Fingerprint (DSF) visualization. The visualization clearly discloses how patient data contributes to the AD state, facilitating rapid interpretation of the information. To model the AD state from complex and heterogeneous patient data, a statistical Disease State Index (DSI) method underlying the DSF has been developed. Using baseline data from the Alzheimer's Disease Neuroimaging Initiative (ADNI), the ability of the DSI to model disease progression from elderly healthy controls to AD and its ability to predict conversion from mild cognitive impairment (MCI) to AD were assessed. It was found that the DSI provides well-behaving AD state estimates, corresponding well with the actual diagnoses. For predicting conversion from MCI to AD, the DSI attains performance similar to state-of-the-art reference classifiers. The results suggest that the DSF establishes an effective decision support and data visualization framework for improving AD diagnostics, allowing clinicians to rapidly analyze large quantities of diverse patient data.
引用
收藏
页码:163 / 176
页数:14
相关论文
共 50 条
  • [41] Adding Recognition Discriminability Index to the Delayed Recall Is Useful to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative
    Russo, Maria J.
    Campos, Jorge
    Vazquez, Siliva
    Sevlever, Gustavo
    Allegri, Richardo F.
    FRONTIERS IN AGING NEUROSCIENCE, 2017, 9
  • [42] Inflammation in mild cognitive impairment due to Parkinson's disease, Lewy body disease, and Alzheimer's disease
    King, Eleanor
    O'Brien, John
    Donaghy, Paul
    Williams-Gray, Caroline H.
    Lawson, Rachael A.
    Morris, Christopher M.
    Barnett, Nicola
    Olsen, Kirsty
    Martin-Ruiz, Carmen
    Burn, David
    Yarnall, Alison J.
    Taylor, John-Paul
    Duncan, Gordan
    Khoo, Tien K.
    Thomas, Alan
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2019, 34 (08) : 1244 - 1250
  • [43] Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease
    Hall, Anette
    Munoz-Ruiz, Miguel
    Mattila, Jussi
    Koikkalainen, Juha
    Tsolaki, Magda
    Mecocci, Patrizia
    Kloszewska, Iwona
    Vellas, Bruno
    Lovestone, Simon
    Visser, Pieter Jelle
    Lotjonen, Jyrki
    Soininen, Hilkka
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 44 (01) : 79 - 92
  • [44] Biomarkers of Alzheimer's disease: The present and the future
    Lehmann, S.
    Delaby, C.
    Touchon, J.
    Hirtz, C.
    Gabelle, A.
    REVUE NEUROLOGIQUE, 2013, 169 (10) : 719 - 723
  • [45] Brain imaging in the study of Alzheimer's disease
    Reiman, Eric M.
    Jagust, William J.
    NEUROIMAGE, 2012, 61 (02) : 505 - 516
  • [46] Microvascular Perfusion Imaging in Alzheimer's Disease
    Song, Yi
    Xing, Hang
    Zhang, Zhiqi
    JOURNAL OF INTEGRATIVE NEUROSCIENCE, 2024, 23 (04)
  • [47] Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease
    Seo, Younghoon
    Jang, Hyemin
    Lee, Hyejoo
    LIFE-BASEL, 2022, 12 (02):
  • [48] The Clinical Value of Large Neuroimaging Data Sets in Alzheimer's Disease
    Toga, Arthur W.
    NEUROIMAGING CLINICS OF NORTH AMERICA, 2012, 22 (01) : 107 - +
  • [49] Analysis of lipophilic fluorescent products in blood of Alzheimer's disease patients
    Chmatalova, Zuzana
    Vyhnalek, Martin
    Laczo, Jan
    Hort, Jakub
    Skoumalova, Alice
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2016, 20 (07) : 1367 - 1372
  • [50] New horizons in the diagnosis and management of Alzheimer's Disease in older adults
    Dolphin, Helena
    Dyer, Adam H.
    Morrison, Laura
    Shenkin, Susan D.
    Welsh, Tomas
    Kennelly, Sean P.
    AGE AND AGEING, 2024, 53 (02)